Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the Nasdaq Global Market under the symbol “AYLA.”

Ayala is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Its differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and, associate David Li. Partner David R. Bauer and associate Jay Frankel provided intellectual property advice. Partner Patrick E. Sigmon and associate Rebecca A. Rosen provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post